Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 211

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A 13-Gene Signature Prognostic of HPV-Negative OSCC: Discovery and External Validation

Open access
Lohavanichbutr, Pawadee, Méndez, Eduardo, Holsinger, F. Christopher, Rue, Tessa C., Zhang, Yuzheng, Houck, John, Upton, Melissa P., Futran, Neal, Schwartz, Stephen M., Wang, Pei, Chen, Chu·2013·Clinical Cancer Research

Abstract

Purpose: To identify a prognostic gene signature for patients with human papilloma virus (HPV)–negative oral squamous cell carcinomas (OSCC). Experimental Design: Two gene expression datasets were used: a training dataset from the Fred Hutchinson Cancer Research Center (FHCRC, Seattle, WA; n = 97) and a validation dataset from the MD Anderson Cancer Center (MDACC, Houston, TX; n = 71). We applied L1/L2-penalized Cox regression models to the FHCRC data on the 131-gene signature previously identified to be prognostic in patients with OSCCs to identify a prognostic model specific for patients with high-risk HPV-negative OSCCs. The models were tested with the MDACC dataset using a receiver operating characteristic (ROC) analysis. Results: A 13-gene model was identified as the best predictor of HPV-negative OSCC-specific survival in the training dataset. The risk score for each patient in the validation dataset was calculated from this model and dichotomized at the median. The estimated 2-year mortality (±SE) of patients with high-risk scores was 47.1% (±9.24%) compared with 6.35% (±4.42) for patients with low-risk scores. ROC analyses showed that the areas under the curve for the age, gender, and treatment modality-adjusted models with risk score [0.78; 95% confidence interval (CI), 0.74–0.86] and risk score plus tumor stage (0.79; 95% CI, 0.75–0.87) were substantially higher than for the model with tumor stage (0.54; 95% CI, 0.48–0.62). Conclusions: We identified and validated a 13-gene signature that is considerably better than tumor stage in predicting survival of patients with HPV-negative OSCCs. Further evaluation of this gene signature as a prognostic marker in other populations of patients with HPV-negative OSCC is warranted. Clin Cancer Res; 19(5); 1197–203. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-2647

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 211

Metadata

Authors
Lohavanichbutr, P., Méndez, E., Holsinger, F. C., Rue, T. C., Zhang, Y., Houck, J., Upton, M. P., Futran, N., Schwartz, S. M., Wang, P., & Chen, C.
Venue
Clinical Cancer Research
Published
2013-03-01
Volume
19
Issue
5
Pages
1197-1203
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2131838114
Cited by
211
References
2
FWCI
5.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 13-Gene Signature Prognostic of HPV-Negative OSCC: Discovery and External Validation. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-2647
The paper
Lohavanichbutr, P., Méndez, E., Holsinger, F. C., Rue, T. C., Zhang, Y., Houck, J., Upton, M. P., Futran, N., Schwartz, S. M., Wang, P., & Chen, C. (2013). A 13-Gene Signature Prognostic of HPV-Negative OSCC: Discovery and External Validation. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-2647

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.